Linked Data API

Show Search Form

Search Results

882727
registered interest false more like this
date less than 2018-04-13more like thismore than 2018-04-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Dermatitis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of adults with atopic dermatitis in (a) Penistone and Stocksbridge constituency, (b) England and (c) the UK. more like this
tabling member constituency Penistone and Stocksbridge more like this
tabling member printed
Angela Smith more like this
uin 135789 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-04-23more like thismore than 2018-04-23
answer text <p>This data is not available, however, the National Institute for Health and Care Excellence estimates that atopic dermatitis (atopic eczema) is a common skin condition that affects between 2–10% of adults.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-04-23T16:18:03.773Zmore like thismore than 2018-04-23T16:18:03.773Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
1564
label Biography information for Angela Smith more like this
882728
registered interest false more like this
date less than 2018-04-13more like thismore than 2018-04-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Skin Diseases more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure patients in England with (a) skin conditions and (b) atopic dermatitis are able to access to new innovative treatments. more like this
tabling member constituency Penistone and Stocksbridge more like this
tabling member printed
Angela Smith more like this
uin 135790 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-04-23more like thismore than 2018-04-23
answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. NICE has published a range of guidance products for the management of skin conditions, including technology appraisals, guidelines and quality standards, which can be accessed at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/conditions-and-diseases/skin-conditions/skin-conditions--general-and-other#technology-appraisal-guidance" target="_blank">https://www.nice.org.uk/guidance/conditions-and-diseases/skin-conditions/skin-conditions--general-and-other#technology-appraisal-guidance</a></p><p> </p><p>National Health Service commissioners are legally required to fund treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>The Government takes the issue of ensuring rapid access to innovative therapies very seriously, which is why on 3 November 2017, we published our response to the Accelerated Access Review. We set out plans to give patients quicker access to life-changing treatments and make the United Kingdom the best place in the world for industry to invest and innovate.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-04-23T15:39:05.96Zmore like thismore than 2018-04-23T15:39:05.96Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
1564
label Biography information for Angela Smith more like this
882730
registered interest false more like this
date less than 2018-04-13more like thismore than 2018-04-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Medical Treatments: Innovation more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in encouraging pharmaceutical companies to launch promising and innovative medicines in the UK. more like this
tabling member constituency Penistone and Stocksbridge more like this
tabling member printed
Angela Smith more like this
uin 135792 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-04-23more like thismore than 2018-04-23
answer text <p>The Life Sciences Industrial Strategy set out our vision of being a world-leader in developing and bringing to market innovative medicines to improve life-chances of United Kingdom patients. It highlighted the importance of evolving and simplifying the access system for new medicines by implementing, and building on, the findings of the Accelerated Access Review.</p><p> </p><p>The Early Access to Medicines Scheme (EAMS) is an essential part of delivering on this ambition. It has been effective in encouraging companies to bring their products to the UK and market them. The figures below show increasing engagement from industry as the scheme has progressed.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>Number of Promising Innovative Medicines awarded</p></td><td><p>8</p></td><td><p>6</p></td><td><p>17</p></td><td><p>20</p></td></tr><tr><td><p>Number of Scientific Opinions awarded</p></td><td><p>1</p></td><td><p>8</p></td><td><p>3</p></td><td><p>7</p></td></tr></tbody></table><p> </p><p>The EAMS task group has been established to provide a forum for industry to engage with the Government, the devolved administrations and arm’s length bodies, driving further improvements to the scheme and making the UK a more attractive place to test and deliver new pharmaceuticals.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-04-23T15:40:30.903Zmore like thismore than 2018-04-23T15:40:30.903Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
1564
label Biography information for Angela Smith more like this